P017 Abemaciclib + endocrine therapy (ET) for HR+, HER2-, node-positive, high-risk EBC: results from a pre-planned monarchE overall survival (OS) interim analysis (IA), including 4-year efficacy outcomes

Podobne zapisy

• Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups
  od: Stephen Johnston, i wsp.
  Wydane: (2021-06-01)
• P017 Abemaciclib + endocrine therapy (ET) for HR+, HER2-, node-positive, high-risk EBC: results from a pre-planned monarchE overall survival (OS) interim analysis (IA), including 4-year efficacy outcomes
  od: S. Johnston, i wsp.
  Wydane: (2023-03-01)
• Efficacy and safety results by menopausal status in monarchE: adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2−, node-positive, high-risk early breast cancer
  od: Shani Paluch-Shimon, i wsp.
  Wydane: (2023-02-01)
• Safety outcomes from monarchE: Phase 3 study of abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER-2-, node-positive, high risk, early breast cancer
  od: H. Rugo, i wsp.
  Wydane: (2021-04-01)
• Patients’ quality of life and side effect perceptions in monarchE, a study of abemaciclib plus endocrine therapy in adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer
  od: S. Tolaney, i wsp.
  Wydane: (2021-04-01)